ADVERTISEMENT

Morgan Stanley Sees Turnaround In Generics Business For Drugmakers

Specialty is going to be the fourth tier after APIs, domestics, exports and generics, according to Baisiwala.



Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah, U.S. (Photographer: George Frey/Bloomberg)
Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah, U.S. (Photographer: George Frey/Bloomberg)

Specialty and generic businesses will continue to do well for pharmaceutical companies, according to Sameer Baisiwala of Morgan Stanley.

The way indian pharma business models are going, specialty is going to be the fourth tier after APIs, domestics, exports and generics, Baisiwala told BloombergQuint in an interview on the sidelines of the Morgan Stanley conference. "There is enough and more opportunities in complex generics which you can expect," Baisiwala added.

Watch the interview here